Conditions: Hypertension With Renal Dysfunction
Keywords: Hypertension Renal dysfunction LCZ696
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.

Detailed description:

Arms:
arm 1: All participants were started on LCZ696 100 mg once daily on day 1. arm 2: All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP \<80 mmHg and msSBP \<130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg. arm 3: All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP \<80 mmHg and msSBP \<130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.

Interventions: intervention 1: LCZ696
Intervention descriptions: intervention 1: 100 mg, 200 mg, 400 mg tablets.

Protocol document: